Monday, March 03, 2025 | 12:53 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Focus on India, emerging markets could drive Dr Reddy's rerating

These markets get a higher valuation compared to the US

Dr Reddy's
Premium

Ujjval Jauhari
Dr Reddy’s has gained about 10 per cent from February lows on expectations that some recovery in the US market and its emerging markets (EMs) focus should improve its growth trajectory.

The company’s performance during the December quarter showed some green shoots, with a 4 per cent sequential growth in the US. 

Analysts believe its US generics business might be finally turning the corner. A few approvals for launches and positive developments on opioid drug Suboxone litigation also bode well, while some relief on regulatory front provides more confidence. The clearance of Duvvada facility by the US drug regulator was

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in